Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.24 Billion KRW | 80.46% |
| 2022 | -83.14 Billion KRW | -546.04% |
| 2021 | -12.87 Billion KRW | -212.59% |
| 2020 | 11.43 Billion KRW | 111.93% |
| 2019 | -95.85 Billion KRW | -1455.79% |
| 2018 | 7.06 Billion KRW | -98.64% |
| 2017 | 518.81 Billion KRW | 6475.41% |
| 2016 | 7.89 Billion KRW | -19.17% |
| 2015 | 9.76 Billion KRW | 365.83% |
| 2014 | 2.09 Billion KRW | 332.6% |
| 2013 | 484.38 Million KRW | -95.66% |
| 2012 | 11.17 Billion KRW | -58.65% |
| 2011 | 27.01 Billion KRW | 6.06% |
| 2010 | 25.47 Billion KRW | -9.03% |
| 2009 | 27.99 Billion KRW | 59.67% |
| 2008 | 17.53 Billion KRW | 28.23% |
| 2007 | 13.67 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -12.26 Billion KRW | -27699.71% |
| 2024 Q1 | 44.42 Million KRW | 100.16% |
| 2023 Q3 | -260.14 Million KRW | -120.67% |
| 2023 Q2 | 1.25 Billion KRW | -93.04% |
| 2023 Q4 | -27.05 Billion KRW | -10301.47% |
| 2023 FY | -16.24 Billion KRW | 80.46% |
| 2023 Q1 | 18.08 Billion KRW | 124.06% |
| 2022 Q3 | -2.8 Billion KRW | -580.75% |
| 2022 Q2 | -412.77 Million KRW | 91.36% |
| 2022 Q1 | -4.77 Billion KRW | 35.28% |
| 2022 FY | -83.14 Billion KRW | -546.04% |
| 2022 Q4 | -75.14 Billion KRW | -2574.25% |
| 2021 Q4 | -7.38 Billion KRW | -832.75% |
| 2021 Q1 | 869.93 Million KRW | -67.36% |
| 2021 Q2 | 2.02 Billion KRW | 132.39% |
| 2021 Q3 | 1 Billion KRW | -50.17% |
| 2021 FY | -12.87 Billion KRW | -212.59% |
| 2020 Q4 | 2.66 Billion KRW | 68.17% |
| 2020 FY | 11.43 Billion KRW | 111.93% |
| 2020 Q1 | 4.13 Billion KRW | 104.26% |
| 2020 Q2 | 3.04 Billion KRW | -26.22% |
| 2020 Q3 | 1.58 Billion KRW | -48.02% |
| 2019 Q2 | 2.57 Billion KRW | 58.01% |
| 2019 Q1 | 1.63 Billion KRW | -20.7% |
| 2019 Q4 | -97.05 Billion KRW | -4551.54% |
| 2019 Q3 | 2.18 Billion KRW | -15.49% |
| 2019 FY | -95.85 Billion KRW | -1455.79% |
| 2018 FY | 7.06 Billion KRW | -98.64% |
| 2018 Q4 | 2.05 Billion KRW | 20.45% |
| 2018 Q3 | 1.7 Billion KRW | -8.95% |
| 2018 Q2 | 1.87 Billion KRW | 31.79% |
| 2018 Q1 | 1.42 Billion KRW | -98.61% |
| 2017 Q2 | 517.89 Billion KRW | 62642.97% |
| 2017 FY | 518.81 Billion KRW | 6475.41% |
| 2017 Q1 | 825.42 Million KRW | -69.68% |
| 2017 Q3 | -102.06 Billion KRW | -119.71% |
| 2017 Q4 | 102.18 Billion KRW | 200.13% |
| 2016 Q1 | 1.94 Billion KRW | 0.0% |
| 2016 Q3 | 711.62 Million KRW | -76.83% |
| 2016 Q4 | 2.72 Billion KRW | 282.61% |
| 2016 Q2 | 3.07 Billion KRW | 57.58% |
| 2016 FY | 7.89 Billion KRW | -19.17% |
| 2015 FY | 9.76 Billion KRW | 365.83% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 1.57 Billion KRW | -57.11% |
| 2015 Q2 | 3.67 Billion KRW | 222.36% |
| 2015 Q1 | 1.14 Billion KRW | 141.96% |
| 2014 Q2 | 3.37 Billion KRW | 234.4% |
| 2014 Q1 | 1 Billion KRW | 129.67% |
| 2014 FY | 2.09 Billion KRW | 332.6% |
| 2014 Q4 | -2.71 Billion KRW | -738.43% |
| 2014 Q3 | 425.55 Million KRW | -87.4% |
| 2013 Q3 | 715.84 Million KRW | 2.56% |
| 2013 Q4 | -3.4 Billion KRW | -575.53% |
| 2013 FY | 484.38 Million KRW | -95.66% |
| 2013 Q1 | 2.47 Billion KRW | 286.58% |
| 2013 Q2 | 697.95 Million KRW | -71.8% |
| 2012 Q4 | -1.32 Billion KRW | -129.61% |
| 2012 FY | 11.17 Billion KRW | -58.65% |
| 2012 Q1 | 4.52 Billion KRW | 21819.31% |
| 2012 Q2 | 3.49 Billion KRW | -22.68% |
| 2012 Q3 | 4.47 Billion KRW | 28.12% |
| 2011 FY | 27.01 Billion KRW | 6.06% |
| 2011 Q4 | 20.63 Million KRW | -99.83% |
| 2011 Q3 | 12.03 Billion KRW | 151.53% |
| 2011 Q2 | 4.78 Billion KRW | -53.22% |
| 2011 Q1 | 10.22 Billion KRW | 46.71% |
| 2010 Q2 | 4.67 Billion KRW | -20.34% |
| 2010 FY | 25.47 Billion KRW | -9.03% |
| 2010 Q4 | 6.97 Billion KRW | -12.36% |
| 2010 Q3 | 7.95 Billion KRW | 70.1% |
| 2010 Q1 | 5.86 Billion KRW | 9.52% |
| 2009 Q1 | 6.48 Billion KRW | 90.64% |
| 2009 Q2 | 7.82 Billion KRW | 20.67% |
| 2009 Q3 | 8.33 Billion KRW | 6.47% |
| 2009 Q4 | 5.35 Billion KRW | -35.66% |
| 2009 FY | 27.99 Billion KRW | 59.67% |
| 2008 Q3 | 4.28 Billion KRW | -36.54% |
| 2008 Q2 | 6.75 Billion KRW | 117.79% |
| 2008 Q1 | 3.09 Billion KRW | -8.64% |
| 2008 Q4 | 3.4 Billion KRW | -20.6% |
| 2008 FY | 17.53 Billion KRW | 28.23% |
| 2007 Q1 | 2.32 Billion KRW | 0.0% |
| 2007 Q4 | 3.39 Billion KRW | -23.64% |
| 2007 Q3 | 4.44 Billion KRW | 26.52% |
| 2007 Q2 | 3.51 Billion KRW | 50.87% |
| 2007 FY | 13.67 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -126.291% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 128.022% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 72.729% |
| HANDOK Inc. | -28.79 Billion KRW | 43.572% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -93.1% |
| Yuhan Corporation | 93.5 Billion KRW | 117.378% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 246.098% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 34.509% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 111.112% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 563.139% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -548.326% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -683.532% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -259.123% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 172.762% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -126.291% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 22.402% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 553.476% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 86.26% |
| JW Holdings Corporation | 19.02 Billion KRW | 185.407% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 79.412% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 107.646% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 143.911% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 71.653% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 365.442% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 1076.817% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 424.687% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -126.291% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 143.959% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 114.574% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 143.911% |
| Yuhan Corporation | 93.5 Billion KRW | 117.378% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -319.289% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 365.552% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 143.911% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 185.951% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 133.67% |
| CKD Bio Corp. | -24.19 Billion KRW | 32.832% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 167.942% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 159.223% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 154.576% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 71.653% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 134.568% |
| Boryung Corporation | 40.2 Billion KRW | 140.419% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 48.133% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -548.326% |
| JW Lifescience Corporation | 28.14 Billion KRW | 157.738% |